Axsome & Antecip v. Teva — Three-Patent Drug Case Consolidated in NJ, 70 Days
Axsome Therapeutics and Antecip Bioventures II filed suit against Teva Pharmaceutical in December 2023, asserting three US patents covering dextromethorphan hydrobromide and bupropion hydrochloride extended-release tablets. Within 70 days, the court consolidated this action with a related earlier case, directing all proceedings forward under Civil Action No. 23-01695.
Three-patent pharma infringement case consolidated into NJ lead action
On December 15, 2023, Axsome Therapeutics, Inc. and Antecip Bioventures II, LLC filed Civil Action No. 2:23-cv-23142 in the District of New Jersey against Teva Pharmaceutical Industries, Ltd., asserting three patents — US11717518B1, US11730706B1, and US11752144B1 — all directed to dextromethorphan hydrobromide and bupropion hydrochloride extended-release tablets. The action was the second filed by the same plaintiffs against Teva in the same court, following an earlier related suit filed March 24, 2023 under Civil Action No. 23-01695.
On February 23, 2024, just 70 days after filing, the court entered a consolidation order merging both civil actions for all purposes, including discovery, case management, and trial. Civil Action No. 23-23142 was administratively terminated by the clerk, with all future filings directed to the lead docket, No. 23-01695. Teva formally accepted service on the December 2023 complaint and filed its answer on January 18, 2024, consistent with the parties’ agreement.
The speed of consolidation — under 10 weeks — suggests the parties and court recognised the significant overlap between the two actions and moved efficiently to streamline proceedings. The consolidated schedule projects claim construction activity extending into late 2024 and fact discovery closing in early 2025, indicating the substantive dispute remains active. The public record of this docket does not reveal settlement discussions or licensing negotiations, and the core infringement and validity questions over all three patents remain unresolved.
Filing to settlement in 70 days
70 days from filing to administrative consolidation — faster than most ANDA patent disputes
What case consolidation means and what happens next
Consolidation merges cases — does not end the litigation
Consolidation under Fed. R. Civ. P. 42(a) allows a court to combine related actions sharing common questions of law or fact. Here, Civil Action No. 23-23142 was merged into the earlier-filed No. 23-01695. The newer docket is administratively terminated — meaning no further filings occur there — but the patents and claims it introduced continue to be litigated in the lead action. No rights are waived or forfeited by either side.
Litigation continuesTeva now faces all three patents on a single consolidated schedule
By consolidating, Teva must defend against US11717518, US11730706, and US11752144 in a single proceeding. The consolidated schedule sets a unified claim construction timeline, with responsive contentions, Markman briefing, and fact discovery all aligned. This can create efficiency for Teva’s defence team but also means there is no opportunity to resolve each patent action separately at its own pace.
Unified defence requiredLead case remains in District of New Jersey under the same judge
The consolidation keeps all proceedings before the same New Jersey District Court, preserving continuity of judicial oversight. The amended schedule established in the February 23, 2024 order governs claim construction for all three patents, with Markman hearing scheduling due December 2024 and fact discovery closing February 7, 2025. No change of venue was ordered or sought.
NJ District Court retainedThree closely filed patents suggest a layered claim strategy by plaintiffs
The three asserted patents — US11717518, US11730706, and US11752144 — share overlapping application dates filed in January–February 2023, consistent with a continuation or related-patent portfolio strategy around the dextromethorphan/bupropion formulation. Filing multiple patents with staggered grant dates is a common approach to maintain assertion flexibility as a generic challenger progresses through regulatory review.
Continuation portfolio signalFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AXSOME THERAPEUTICS, INC. | Company | Pharmaceutical IP holder — asserting US11717518, US11730706 & US11752144 on CNS drug formulationSearch in Eureka ↗ |
| Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Teva Pharmaceutical Industries, Ltd. — global generic and specialty drug manufacturerSearch in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for AXSOME THERAPEUTICS, INC.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for AXSOME THERAPEUTICS, INC.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for AXSOME THERAPEUTICS, INC.Search in Eureka ↗ |
| Defendant counsel | Christine Intromasso Gannon | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Liza M. Walsh | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Patrick Steven Salamea | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge / | Chief Judge | New Jersey District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The February 23, 2024 consolidation order is procedural rather than substantive — it does not adjudicate infringement, validity, or any merits question. The order administratively terminates Civil Action No. 23-23142 but expressly preserves all claims, including those under the ‘518, ‘706, and ‘144 patents, within the consolidated lead action. For both parties, this means the litigation clock resets to a unified amended schedule, and no legal rights are altered. The core dispute over Teva’s generic dextromethorphan/bupropion product remains fully live.
US11717518, US11730706 & US11752144 — Dextromethorphan/Bupropion ER Tablets
The three asserted patents — US11717518B1, US11730706B1, and US11752144B1 — all relate to extended-release tablet formulations combining dextromethorphan hydrobromide (DXM) and bupropion hydrochloride. DXM is an NMDA receptor antagonist and sigma-1 receptor agonist; bupropion is a norepinephrine-dopamine reuptake inhibitor that also inhibits DXM metabolism, raising its plasma levels. The combination is the basis of Axsome’s branded CNS product. The patents’ application numbers (US18/157393, US18/158268, US18/173291) were filed in January–February 2023, suggesting a rapid continuation strategy following initial grant.
From a strategic standpoint, these patents represent Axsome’s principal IP barrier against generic market entry for its dextromethorphan/bupropion combination product. The layered portfolio — three separately granted patents covering overlapping aspects of the same formulation — is designed to maximise litigation leverage and the regulatory exclusivity period. For competitors and generic manufacturers, the breadth of this portfolio means that designing around a single patent may be insufficient; all three grants would need to be invalidated or distinguished to enable a clear path to market. The patents are likely to be closely scrutinised for claim differentiation during Markman proceedings.
Should your product team run an FTO against US11717518, US11730706 & US11752144?
Any company developing, formulating, or seeking regulatory approval for a generic or novel product combining dextromethorphan with bupropion — particularly in extended-release oral dosage form — should treat these three patents as high-priority FTO targets. The active consolidated litigation confirms that Axsome and Antecip are willing and prepared to enforce this portfolio aggressively. Even minor formulation differences may not be sufficient to avoid infringement if the core pharmacokinetic mechanism falls within claim scope.
PatSnap Eureka’s FTO Search Agent can map all three patent numbers against your product’s composition, release mechanism, and dosage parameters to identify claim overlap and whitespace. Eureka’s claim monitoring feature will also alert your team to any continuation filings or related applications that may extend the portfolio beyond the three currently asserted patents — a particularly relevant risk given the rapid sequential filing pattern visible in this case’s application numbers.
Run a freedom-to-operate analysis on US11717518B1 to assess your product’s exposure
Run FTO in Eureka →Similar pharmaceutical patent consolidation cases in NJ District Court
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the CNS pharmaceutical patent landscape
Axsome’s multi-patent assertion against Teva reflects intensifying IP competition in the CNS drug space — particularly around novel combination formulations.
Multi-patent filings against generics are becoming the norm in CNS pharma
Axsome and Antecip’s strategy of filing two separate civil actions and then consolidating them is consistent with ANDA-era litigation playbooks: assert every available patent to maximise the 30-month stay and extend market exclusivity. Companies holding CNS combination-drug patents should audit their portfolio for continuation opportunities before generic ANDA filings arrive.
Teva’s acceptance of service signals a prepared defence — not a concession
Teva’s prompt acceptance of service and timely answer in Civil Action No. 23-23142 suggests an organised litigation posture, likely because it was already engaged in the parallel 23-01695 action. Generic challengers with existing counsel on related dockets typically move faster and with lower incremental cost — a dynamic that can reduce settlement leverage for brand-side plaintiffs.
AXSOME v Teva — key questions answered
Civil Action No. 2:23-cv-23142 was a patent infringement suit filed by Axsome Therapeutics and Antecip Bioventures II against Teva in December 2023, asserting three patents on dextromethorphan/bupropion extended-release tablets. On February 23, 2024, the court consolidated it with the earlier-filed related case No. 23-01695. The newer docket was administratively terminated; all litigation continues under the lead action.
Axsome and Antecip asserted US11717518B1, US11730706B1, and US11752144B1. All three patents relate to extended-release tablet formulations combining dextromethorphan hydrobromide and bupropion hydrochloride, the active ingredients in Axsome’s CNS drug product. The application numbers suggest all three were filed in January–February 2023.
The case was administratively terminated — not dismissed — as a result of consolidation with Civil Action No. 23-01695. Administrative termination is a procedural step that closes the secondary docket for filing purposes, while all substantive claims, parties, and schedules transfer to the lead docket. The infringement dispute against Teva remains fully active.
Consolidation means Teva now defends all three asserted patents — US11717518, US11730706, and US11752144 — in a single proceeding with a unified schedule. Teva’s answer to counterclaims and invalidity contentions are governed by the amended schedule set in the February 2024 consolidation order. There is no option to resolve the December 2023 complaint separately from the March 2023 action.
Axsome Therapeutics and Antecip Bioventures II are represented by Saul Ewing LLP, with attorneys Charles Michael Lizza, Sarah Ann Sullivan, and William C. Baton listed. Teva Pharmaceutical is represented by Walsh Pizzi O’Reilly Falanga LLP, with attorneys Christine Intromasso Gannon, Liza M. Walsh, and Patrick Steven Salamea listed on the docket.
PatSnap Eureka searches patents and litigation data to answer instantly.